The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (21 analysts) rates it buy, with a mean price target of $89.
Corteva
CTVA · a US exchange · USD · Market cap $8.6B · 21,500 employees
Corteva, Inc.
PASS · Titan Ethical · score 90.0Price as of 28 Oct 2026Daily close, not a live quote
Screened 2026-10-28 · the tape above runs as of 06:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price11.33 USD at the 28 Oct 2026 close
- Our ratingFair value, current read distribution
- Ethical screenPasses, score 90.0 out of 100
- OptionsOpen interest leans to puts (put/call 2.82)
- Last reviewed28 Oct 2026 (1 days ago)
A summary of the dated readings below, not a live quote and not advice.
What this means: price 11.33 against the desk's fair-value range, base estimate 11.81, over the last year.
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning political selling, disclosed 2026-09-17
- Options put/call open interest 2.82, read 2026-10-28
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Corteva holds its Distribution at $11.33. Consolidating, no directional conviction, held for 16 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 16 days |
| Price at the screen | $11.33 |
| Valuation | 7.95 trailing · 11.38 forward price to earnings |
| Values screen | PASS · score 90.0 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 6.02% | Below 33% | Interest-bearing debt is just 6.0% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.37% | Below 33% | Cash held in interest-bearing accounts and securities is 0.4% of assets, under the one-third limit. | Pass |
| Receivables | 22.30% | Below 49% | Money owed to the company is 22.3% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.78% | Below 5% | Only 0.8% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
Corteva clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 6%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CTVA's ethical verdict changes
Today CTVA passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads FAIR VALUE: it trades at roughly a 4% discount to our $11.81 fair value, narrow competitive moat.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. A 4.2% margin of safety to the base estimate.
Third-party analyst targets: 11 covering, consensus Buy. The average target sits +50% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsSeeds and sprays priced for perfect harvests
Picture a farmer locking in next season's seed at a fat premium while the weather, pests and grain prices stay wild cards. Corteva sits in that spot right now. At 21 times forward earnings the shares trade well above our fair value with a negative margin of safety, and the narrow moat plus low single-digit ROE give little cushion when cycles turn.
The business splits between seeds and crop protection, both tied to farm incomes that swing with commodity prices and weather. Revenue growth looks solid at 11 percent, yet a 6 percent profit margin and 5 percent return on equity hardly scream durable advantage in a cyclical field. Analysts may cluster around a buy rating, but the valuation already prices in smooth sailing.
Cyclical names often flash cheap multiples at peak earnings; here the multiple is not cheap and the earnings can still fall fast. Currency moves, regulation on crop chemicals and sudden drops in planted acres all sit outside management control. Analysis, not advice.
| Forward P/E | 11.4xreasonably valued |
| Trailing P/E | 8.0xvery cheap relative to earnings |
| EPS, trailing | 1.62 |
| EPS, forward | 1.13 |
| Revenue growth | -1.2%revenue is shrinking |
| Profit margin | 2.8%barely profitable |
| Dividend yield | 0.86% |
| Debt to equity | 0.57moderate, manageable leverage |
| Current ratio | 1.79healthy short-term liquidity |
| Short interest, float | 0.04% |
| 52-week range | 9.08 - 14.62 |
| Moat | NARROW |
| Market cap | $8.6B |
| Employees | 21,500 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeCTVA trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 83.6% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (21 analysts) rates it buy, with a mean price target of $89.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (21 analysts) rates it buy, with a mean price target of $89.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.2% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (21 analysts) rates it buy, with a mean price target of $89.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 9.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (21 analysts) rates it buy, with a mean price target of $89.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 13.3% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (21 analysts) rates it buy, with a mean price target of $89.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (21 analysts) rates it buy, with a mean price target of $89.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (90). The risk-adjusted return profile shows good risk-adjusted returns.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with near-perfect ethical score (90). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Corteva Declares Quarterly Dividend Yahoo Finance · 6d ago
- What You Need To Know Ahead of Corteva's Earnings Release Yahoo Finance · 12d ago
- Can Prepared Foods Become Mission Produce's Next Growth Engine? Yahoo Finance · 13d ago
- FMC Stock Dropped 31%—Why It May Still Be No Bargain Yahoo Finance · 13d ago
- FMC Stock Crashes 33% On Massive Earnings Downgrade – Citi expects ‘Modest Negative Reaction’ For Peer Corteva Yahoo Finance · 14d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-30 | GIESSELMAN JANET PLAUT | Director | 95 | $7,750 | |
| 2026-04-30 | NAYYAR NAYAKI R | Director | 401 | $32,500 | |
| 2026-04-28 | GIESSELMAN JANET PLAUT | Director | 2,350 | · | |
| 2026-04-28 | PAGE GREGORY R | Director | 3,870 | · | |
| 2026-04-28 | EVERITT DAVID C | Director | 2,350 | · | |
| 2026-04-28 | WARD PATRICK J | Director | 2,350 | · | |
| 2026-04-28 | PREETE KERRY J | Director | 2,350 | · | |
| 2026-04-28 | POLICINSKI CHRISTOPHER J | Director | 2,350 | · | |
| 2026-04-28 | LUTZ MARCOS M | Director | 2,350 | · | |
| 2026-04-28 | NAYYAR NAYAKI R | Director | 2,350 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-09-17 | Gil Cisneros | Democrat | sell | 1K–15K |
| 2026-09-17 | Gil Cisneros | Democrat | sell | 1K–15K |
| 2026-09-04 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-09-04 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-05-15 | Ro Khanna | Democrat | sell | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $82.64 | -9.1% | $0.18 | $912 | -8.8% |
| 2 months | $83.64 | -10.1% | $0.18 | $901 | -9.9% |
| 3 months | $79.57 | -5.5% | $0.18 | $947 | -5.3% |
| 6 months | $65.74 | +14.3% | $0.36 | $1,149 | +14.9% |
| 1 year | $70.86 | +6.1% | $0.72 | $1,071 | +7.1% |
| 2 years | $50.66 | +48.4% | $1.40 | $1,511 | +51.1% |
| 3 years | $54.61 | +37.6% | $2.04 | $1,414 | +41.4% |
| 5 years | $42.19 | +78.1% | $3.20 | $1,857 | +85.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CTVA does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.